Although it is not a blood-based marker, it is important to mention that ExoDx Prostate, a commercialized, urine-based test evaluates 3 EV-derived mRNAs, used to identify high-grade prostate cancer in patients with previous negative biopsies or with low initial PSA values [173]. This evidence concerns the gene PROS1 and prostate carcinoma.